Pfizer lifts 2026 forecasts as Eliquis and cancer drugs offset falling Covid sales
The raise shows Pfizer's post-pandemic reset is taking hold, with growth from acquired oncology assets and its anticoagulant replacing declining Covid revenue.
Read at MedWatch →Full coverage · 11 outlets
- MedWatch · lead
- ReutersPfizer raises 2026 forecasts as Eliquis, cancer drugs drive third-quarter results
- pharma.economictimes.indiatimes.comPfizer raises 2026 forecasts as Eliquis, cancer drugs drive third-quarter results
- Stock TitanPfizer Earnings Show Its Newer Medicines Selling 32% More
- The Edge SingaporePfizer raises 2026 forecast, extending pharma windfall
- The Pharma LetterPfizer raises 2026 revenue guidance as new products offset COVID-19 decline
- BNN BloombergPfizer beats earnings estimates, targets US$2.5 billion in additional cost cuts
- BigGo FinancePfizer Lifts 2026 Revenue Floor by $1 Billion as Non-Covid Drugs Outperform
- Pulse 2.0Pfizer: Raises 2026 Revenue Guidance By $500 Million As Non-COVID Products Outperform By $1.5 Billion
- Cirebon TimesPfizer Raises 2026 Outlook as New Products Drive Growth
- MSNPfizer raises 2026 forecasts as Eliquis, cancer drugs drive third-quarter results